Udai Banerji

Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study

Udai Banerji, Carla M.L. van Herpen, Cristina Saura et al. · The Lancet Oncology · 2019 · 549 citations · Full text

Breast Oncology, Her2-expressing Breast Cancer, Medicine +9

Phase I Pharmacokinetic and Pharmacodynamic Study of 17-Allylamino, 17-Demethoxygeldanamycin in Patients With Advanced Malignancies

Udai Banerji, Anne O’Donnell, Michelle Scurr et al. · Journal of Clinical Oncology · 2005 · 488 citations · Full text

AKT Inhibition in Solid Tumors With <i>AKT1</i> Mutations

David M. Hyman, Lillian M. Smyth, Mark T.A. Donoghue et al. · Journal of Clinical Oncology · 2017 · 315 citations · Full text

Phase I Trial of First-in-Class ATR Inhibitor M6620 (VX-970) as Monotherapy or in Combination With Carboplatin in Patients With Advanced Solid Tumors

Timothy A. Yap, Brent O’Carrigan, Marina S. Penney et al. · Journal of Clinical Oncology · 2020 · 237 citations · Full text

The First-in-Human Study of the Hydrogen Sulfate (Hyd-Sulfate) Capsule of the MEK1/2 Inhibitor AZD6244 (ARRY-142886): A Phase I Open-Label Multicenter Trial in Patients with Advanced Cancer

Udai Banerji, D. Ross Camidge, Henk M.W. Verheul et al. · Clinical Cancer Research · 2010 · 209 citations